文献速递类风湿关节炎

DMARDs减量期间疾病复发对类风湿关节炎患者生活的影响

The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients.
PubMed 文献 · Semin Arthritis Rheum · 2020-02-29

基于TARA试验数据,比较RA患者在DMARDs减量期间出现复发前后的患者报告结局。复发对整体健康、晨僵、HAQ-DI、EQ-5D、BRAF-MDQ及SF36躯体成分量表有负面影响,效应持续>3个月,躯体结局效应>6个月,效应量多超过MCID,但 worker productivity 未受显著影响。

要点

  • 复发对整体健康、晨僵、功能和多个生活质量量表有负面影响。
  • 除HAQ-DI外,效应量超过最小临床重要差异,躯体效应持续>6个月。
  • 个体患者中复发仍可能非常重要,尽管组水平效应不总是显著。

核心结论

  • 疾病复发影响RA患者生活,躯体结局效应最大且持续6个月。

研究设计与样本

  • 基于TARA多中心随机对照试验,纳入疾病控制良好(DAS≤2.4且SJC≤1)至少6个月的RA患者,逐渐减量DMARDs。

主要发现

  • 复发对整体健康、晨僵、HAQ-DI、EQ-5D、BRAF-MDQ及SF36躯体成分量表有负面影响,效应持续>3个月。
  • 除HAQ-DI外,效应量超过最小临床重要差异(MCID)。
  • 躯体结局效应持续>6个月。
  • worker productivity 未受复发显著影响。

关键数值与推荐

  • 复发定义为DAS>2.4和/或SJC>1。
  • 疾病控制良好定义为DAS≤2.4且SJC≤1至少6个月。
  • 采用线性混合模型比较复发前后每3个月的患者报告结局与自身正常值。

临床怎么用

  • 在DMARDs减量期间应监测复发,关注躯体功能和生活质量的持续影响。

局限性

  • 组水平效应量并非总是显著或超过MCID,但个体患者中复发仍可能重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the impact of a disease flare on patient reported outcome measures (PROMs) in rheumatoid arthritis (RA) patients, who are tapering treatment. METHODS: Data were used from the TARA trial; a multicenter, randomized controlled trial in which RA patients, with a well-controlled disease (DAS≤2.4 and SJC≤1) for at least 6 months, gradually tapered their DMARDs. PROMs of patients with a flare (DAS>2.4 and/or SJC>1) were compared every three months before and after a flare with their own norm values. Linear Mixed Models were used to investigate whether a disease flare influenced functional ability (HAQ-DI), fatigue (BRAF-MDQ), quality of life (EQ-5D and SF36), anxiety and depression (HADS), morning stiffness, general health (GH) and worker productivity, and if so, the duration was determined. For unemployment and sick leave we used descriptive statistics. RESULTS: A flare negatively influenced GH, morning stiffness, HAQ-DI, EQ-5D, BRAF-MDQ, and the SF36 physical component scale and this effect lasted >3 months. Except for the HAQ-DI, effect sizes exceeded the minimum clinically important differences (MCIDs). For the physical outcomes effects lasted >6 months. Worker productivity was not significantly affected by a flare. CONCLUSION: A disease flare influenced patients' lives, the largest effect was seen in the physical outcomes, and lasted 6 months. Although on a group level effect sizes for the separate PROMs were not always significant or larger than specific MCIDs, a disease flare can still be of great importance for individual patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. van Mulligen E, Weel AEAM, Kuijper TM, et al. The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients. Semin Arthritis Rheum. 2020. PMID: 32224045. doi:10.1016/j.semarthrit.2020.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。